Chris Ryan
A federal jury in Delaware reportedly found that Japan’s Nippon Shinyaku infringed Sarepta’s rights (NASDAQ:SRPT) patented its Duchenne muscular dystrophy, or DMD, drug Vyondys 53 and awarded Sarepta $115.2 million in damages.
The jury also rejected Shinyaku’s claim that